Solventum's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Solventum's ROA in the second quarter of 2026?
Solventum Corporation achieved a return on average assets (ROA) of 10.03 % in its second quarter of 2026, this is above SOLV's average return on assets of 7.14%.
Solventum Corporations assets during the 12 months ending in the second quarter of 2026 are valued at $14 billion

ROA has improved compared to 9.8% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 95 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 608, from total ROA ranking in the first quarter of 2026 at 641.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-8.45 %	-6.83 %	-8.82 %	-8.7 %	-1.35 %
Y / Y Net Income Change	2.22 %	-90.51 %	103.23 %	937.7 %	1.12 %
Net Income (TTM) in million	1,434	1,432	1,556	1,524	380
Return On Assets (TTM)	10.03 %	9.8 %	10.46 %	10.01 %	2.44 %
SOLV's Total Ranking	# 608	# 641	# 573	# 1676	# 1686
Total Assets (TTM) in million	14,243	14,097	14,294	14,529	15,557
Seq. Total Assets Change	1.04 %	-1.38 %	-1.62 %	-6.61 %	2.82 %
Seq. Net Income Change	607.69 %	-79.37 %	-95.02 %	1306.67 %	-34.31 %

SOLV's 5 Years Annual ROA >> Back to SOLV Management Effectiveness >> Compare SOLV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 27
Sector	# 96
Overall	# 592

Return On Assets Statistics
High	Average	Low
10.76 %	7.14 %	2.61 %
(Dec 31 2025)		(Jun 30 2025)

Financial Statements
Solventum's Assets	$ 14,243 million	SOLV's Balance sheet
Solventum's Income	$ 92 million	Quarterly SOLV's Income Statement
SOLV's Income by Division		See SOLV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	FY	FY	FY
Y / Y Total Assets Change	-19.97 %	-	-	-	-
Total Assets in million	12,546	15,676	0	0	0
Y / Y Net Income Change	224.84 %	-	-	-	-
Net Income in million	1,556	479	0	0	0
Annual Return On Assets	12.4 %	3.06 %	-	-	-

SOLV's 5 Years Annual ROA >> Back to SOLV Management Effectiveness >> Compare SOLV ROA to its Competitors

Comment on SOLV's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 12.4 % compared to prior year, due to annual net income growth of 224.84 % to $1,556.00 million, and due to decline of value in Solventum's assets by -19.97 % to $12,546.00 million, compared to $12,546.00 a year before.

More Return On Assets Ratios
SOLV's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SOLV's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SOLV's Competitors
Subscribers only: Roa for Solventum's Suppliers
Subscribers only: Return On Assets for SOLV's Customers

You may also want to know
SOLV's Roi	SOLV's Inventory Turnover Ratio	SOLV's Growth Rates	SOLV's Dividend Comparisons
	SOLV's Profitability Ratios	SOLV's Asset Turnover Ratio	SOLV's Dividend Growth
SOLV's Roe	SOLV's Valuation Ratios	SOLV's Financial Strength Ratios	SOLV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %

Date modified: 2026-09-09T00:27:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.